Acid Sphingomyelinase: A New Drug Target to Regulate Apoptosis

SK 737

Summary of Invention

The present invention relates to methods and compositions for the modulating acid sphingomyelinase (ASM)-related processes, including apoptosis. ASM-related apoptosis can be induced by environmental stressors, such as ionizing radiation and chemotherapeutic agents. Apoptosis can be characterized by a cellular morphology comprising cellular condensation, nuclear condensation, or zeiosis. The present invention further relates to methods for the identification of compounds, which modulate (i.e., either increase or decrease) sensitivity to ASM-related processes, including apoptosis.


Methods for identifying compounds that increase or decrease a cell’s sensitivity to acid sphingomyelinase-related apoptosis.

Areas of Application

Research tool

Stage of Development

In vivo proof of principle obtained

Lead Inventor

Richard N. Kolesnick, MD, Laboratory Head, Molecular Pharmacology & Chemistry Program, Sloan Kettering Institute, Memorial Sloan Kettering

Patent Information

U.S. patents issued:


Contact Information

Zhenyan Yan, PhD
Licensing Manager
Tel. 646-888-1081

Stage of Development

Ready to use